CALR

Calreticulin · P27797 · CALR on Sugi Atlas →

0 patent compounds predicted against CALR, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CALR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients PHASE2RECRUITING
Targeting the Tumor Microenvironment in R/M SCCHN PHASE1/PHASE2UNKNOWN
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors PHASE1/PHASE2RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies PHASE1/PHASE2NOT_YET_RECRUITING
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) PHASE1/PHASE2RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) PHASE1/PHASE2RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm PHASE1RECRUITING
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms PHASE1COMPLETED
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia PHASE1COMPLETED
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia PHASE1RECRUITING
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia PHASE1COMPLETED
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer EARLY_PHASE1RECRUITING
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma EARLY_PHASE1UNKNOWN
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases EARLY_PHASE1RECRUITING
CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma EARLY_PHASE1ACTIVE_NOT_RECRUITING
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia EARLY_PHASE1RECRUITING
Characteristics of Patients With Philadelphia Negative Myeloproliferative Neoplasms at Assiut University Hospital nanUNKNOWN
Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms nanCOMPLETED
Ruxolitinib in Patients With Myelofibrosis nanUNKNOWN
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms nanRECRUITING
Evaluation of the Pathobiology of CALR-mutated MPN Cells nanRECRUITING
Detection of Circulating Biomarkers of Immunogenic Cell Death nanCOMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? nanRECRUITING
Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells nanRECRUITING
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant nanNOT_YET_RECRUITING
Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS nanNOT_YET_RECRUITING
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CALR binder may also engage these)

ProteinNameSimilarity
Q4VIT5 1.000 Q4VIT5 →
Q4R6K8 1.000 Q4R6K8 →
Q2HWU3 1.000 Q2HWU3 →
P14211 1.000 P14211 →
Q8K3H7 1.000 Q8K3H7 →
P52193 1.000 P52193 →
P28491 1.000 P28491 →
P18418 1.000 P18418 →
P15253 1.000 P15253 →
P29413 0.997 P29413 →
Q7Z1E6 0.995 Q7Z1E6 →
P93508 0.995 P93508 →
O81919 0.993 O81919 →
P35564 0.992 P35564 →
Q06814 0.992 Q06814 →
Q9ZPP1 0.991 Q9ZPP1 →
Q61KR9 0.990 Q61KR9 →
P27798 0.989 P27798 →
P24643 0.989 P24643 →
CANX Calnexin 0.989 landscape →
Q9ZNY3 0.988 Q9ZNY3 →
Q9SLY8 0.987 Q9SLY8 →
O04151 0.987 O04151 →
P35565 0.987 P35565 →
P11012 0.987 P11012 →
Q9SP22 0.986 Q9SP22 →
Q38858 0.986 Q38858 →
P52194 0.985 P52194 →
Q9XF98 0.985 Q9XF98 →
Q5R440 0.984 Q5R440 →